Mepolizumab intravenous (IV) vs placebo
Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 369 participantsHigh
Findings
What do systematic reviews say?
1,017 questions · 1,061 findings · 131 reviews
No studies found 193 · 18.2%GRADE not reported 65 · 6.1%Very low 237 · 22.3%Low 325 · 30.6%Moderate 187 · 17.6%High 54 · 5.1%
Mepolizumab intravenous (IV) vs placebo
Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 369 participantsHigh
Mepolizumab intravenous (IV) vs placebo
FEV1 · people with asthma
1 finding from 1 review
- no estimate extracted2 studies · 690 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Serious adverse events · people with asthma
Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.59 [0.37, 0.94]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Clinically significant adverse events leading to discontinuation · people with asthma
Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).
1 finding from 1 review
- Risk ratio 0.72 [0.18, 2.92]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.53 [0.44, 0.64]3 studies · 751 participantsHigh
Mepolizumab intravenous (IV) vs placebo
Rate of exacerbations requiring emergency department treatment or admission · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).
1 finding from 1 review
- Rate ratio 0.52 [0.31, 0.87]2 studies · 690 participantsHigh
Intravenous opioid analgesics vs placebo or no treatment
Pain intensity (0‐10cm visual analogue scale) · Women being investigated for infertility
1 finding from 1 review
- no estimate extracted1 study · 62 participantsModerate
Summary of findings table ‐ Enteral tube feeding vs intravenous fluids
Successful insertion of intravenous fluid/enteral tube fluid at first attempt · health problem or population
Summary of findings table ‐ Enteral tube feeding probably leads to higher successful insertion of intravenous fluid/enteral tube fluid at… compared with intravenous fluids (moderate certainty).
1 finding from 1 review
- Parenteral versus enteral fluid therapy for children hospitalised with bronchiolitis 2021 · Cochrane Headline outcomes onlyRR 1.52 [1.36, 1.69]1 study · 617 participantsModerate
Intravenous magnesium sulphate vs placebo
Change in frequency of vaso‐occlusive painful crises (as measured by pain diary days with significant pain) · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 104 participantsModerate
Intravenous magnesium sulphate vs placebo
HRQoL score (Child‐reported PedsQL generic scale) at 1 week · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 202 participantsLow
Intravenous magnesium sulphate vs placebo
HRQoL score (Child‐reported PedsQL multidimensional fatigue scale) at 1 week · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 202 participantsLow
Intravenous magnesium sulphate vs placebo
HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 202 participantsLow
Intravenous magnesium sulphate vs placebo
Length of hospital stay · people with sickle cell disease
1 finding from 1 review
- no estimate extracted1 study · 104 participantsLow
Intravenous magnesium sulphate vs placebo
Hypotension · people with sickle cell disease
Intravenous magnesium sulphate showed no clear difference in adverse effects: hypotension compared with placebo (low certainty).
1 finding from 1 review
- RR 2.57 [0.5, 13.08]2 studies · 306 participantsLow
Intravenous magnesium sulphate vs placebo
Adverse effects: warmth at infusion site · people with sickle cell disease
Intravenous magnesium sulphate may leads to higher adverse effects: warmth at infusion site compared with placebo (low certainty).
1 finding from 1 review
- RR 13.26 [3.23, 54.4]1 study · 202 participantsLow
(RCT) Safe intravenous systems vs regular systems
Number of reported sharps injuries, level · preventing percutaneous exposure injuries caused by needles in healthcare personnel
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 2 participantsVery low
(RCT) Safe intravenous systems vs regular systems
Number of reported sharps injuries, slope · preventing percutaneous exposure injuries caused by needles in healthcare personnel
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 2 participantsVery low
(RCT) Safe intravenous systems vs regular systems
Needlestick injuries · preventing percutaneous exposure injuries caused by needles in healthcare personnel
It is very uncertain whether (RCT) Safe intravenous systems changes needlestick injuries compared with regular systems (very low certainty).
2 findings from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRate ratio 0.62 [0.27, 1.41]1 study · 1 participantsVery low
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRate ratio 0.06 [0, 1.09]1 study · 1 participantsVery low
(RCT) Safe intravenous systems vs regular systems
Incidences of blood contamination ‐ Active systems · preventing percutaneous exposure injuries caused by needles in healthcare personnel
(RCT) Safe intravenous systems may leads to higher incidences of blood contamination ‐ Active systems compared with regular systems (low certainty).
1 finding from 1 review
- Devices for preventing percutaneous exposure injuries caused by needles in healthcare personnel 2017 · Cochrane Headline outcomes onlyRR 1.6 [1.08, 2.36]4 studies · 961 participantsLow